Eli Lilly is buying a psychedelic drugmaker in a $2.8 billion deal Jul 16, 2026 · Cris Tolomia The deal gives Lilly access to a DMT-based nasal spray for treatment-resistant depression that has received FDA Breakthrough Therapy Designation Read more »
.jpg?branch=production)
.png?branch=production)
.jpg?branch=production)
